<DOC>
	<DOCNO>NCT02640989</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity three seasonal trivalent influenza vaccine ( TIVs ) manufacture Glaxosmith Kline ( GSK ) , Beijing Sinovac Biotech ( Sinovac ) Shenzhen Sanofi Pasteur ( Pasteur ) Chinese healthy serviceman . Using imported GSK 's TIV control , compare two domestic TIVs Chinese healthy serviceman .</brief_summary>
	<brief_title>Safety Immunogenicity Three Seasonal Trivalent Influenza Vaccines China Military</brief_title>
	<detailed_description>This study 1:1:1 randomize , double-blinded , controlled phase Ⅳ clinical trial military command Beijing . Healthy individual age 18～34 year receive influenza vaccine recent three year enrol administrate one dose TIV . Safety data collect whole study ( Day 0 Day 30 ) .Blood sample collect immunogenicity assessment injection 21 day vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy serviceman age 1834 year , receive influenza vaccine recent three year ; Proven legal identity ; Written inform consent ; Complying requirement study protocol ; Pregnant , breast feeding woman ; History allergy vaccine vaccine ingredient ; Receipt immunosuppressant within 6 month prior study entry ; Congenital malformation , developmental disorder , serious chronic disease , autoimmune disease , immunodeficiency , serious cardiovascular disease , diabetes , GuillainBarré syndrome , hypertension stabilize medication , liver kidney disease , malignant tumor ; Acute disease acute stage chronic disease within 7 day prior study entry ; Axillaty temperature &gt; 37.0 °C ; Any factor opinion investigator suggest volunteer unsuitable study ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Influenza Vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>